Synthesis of novel 5-substituted 3-amino-3,4-dihydro-2H-1-benzopyran derivatives and their interactions with the 5-HT(1A) receptor

Journal of Medicinal Chemistry

Volumn 43, Issue 15, 2000, Pages 2837-2850

  Hammarberg, Eva ^a   Nordvall, Gunnar ^a   Leideborg, Robert ^a   Nylöf, Martin ^a   Hanson, Sverker ^a   Johansson, Lars ^a   Thorberg, Seth Olov ^a   Tolf, Bo Ragnar ^a   Jerning, Eva ^a   Svantesson, Gun Torell ^a   Mohell, Nina ^a   Ahlgren, Charlotte ^a   Westlind Danielsson, Anita ^a   Csöregh, Ingeborg ^b   Johansson, Rolf ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 (N CYCLOPENTYL N PROPYLAMINO) 3,4 DIHYDRO N METHYL 2H 1 BENZOPYRAN 5 CARBOXAMIDE; 8 [4 [N (2 METHYLPROPYL) N (3,4 DIHYDRO 5 METHYLCARBAMOYL 2H 1 BENZOPYRAN 3 YL)AMINO]BUTYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; 8 [4 [N PROPYL N (3,4 DIHYDRO 5 METHYLCARBAMOYL 2H 1 BENZOPYRAN 3 YL)AMINO]BUTYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; BENZOPYRAN DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENANTIOMER; MALE; NONHUMAN; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; CELL LINE; CEREBRAL CORTEX; CORPUS STRIATUM; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; HIPPOCAMPUS; HUMANS; MALE; MODELS, MOLECULAR; PYRANS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0034721173     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990956o     Document Type: Article

References (38)

1. Dunner, D.; Kumar, R. Paroxetine: A review of clinical experience. Pharmacopsychiatry 1998, 31, 89-101.
2. Lapeyre-Mestre, M.; Desboeuf, K.; Aptel, I.; Chale, J.-J.; Montastruc, J.-L.A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists. C. Drug Invest. 1998, 16, 53-61.
3. Houck, C. An open-label pilot study of fluvoxamine for mixed anxiety-depression Psychopharmacol. Bull. 1998, 34, 225-227.
4. Noble, S.; Benfield, P. Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997, 8, 410-431.
5. Baldwin, D. S.; Birtwistle, J.; Lecrubier, Y.; Baldwin.; Den Boer, J. A.; Kasper, S.; Nutt, D. J. The side effect burden associated with drug treatment of panic disorder. J. Clin. Psychiat. 1998, 59 (Suppl. 8), 39-46.
6. Montgomery, S. A.; Kasper, S. Side effects, dropouts from treatment and cost consequences. Int. Clin. Psychopharmacol. 1998, 13 (Suppl. 2), S1-S5.
7. Stassen, H. H.; Angst, J. Delayed onset of action of antidepressants: Fact or fiction? CNS Drugs 1998, 9, 177-184.
8. Blier, P.; de Montigny, C.; Chaput, Y. A. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J. Clin. Psychiat. 1990, 51, 14-20.
9. de Vry, J. 5-HT1A Receptors in Psychopathology and the Mechanism of Action of Clinical Effective Therapeutic Agents. Drugs News Perspect. 1996, 9, 270-280.
10. Dong, J.; de Montigny, C.; Blier, P. Effect of acute and repeated versus sustained administration of the 5-HT(1A) receptor agonist ipsapirone: Electrophysiological studies in the rat hippocampus and dorsal raphe. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 356, 303-311.
11. Blier, P.; Bergeron, R.; de Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997, 16, 333-338.
12. Mason, J. P.; Dring, L. G.; Caldwell, J. Pharmacokinetics of the 5-hydroxytryptamine(1A) agonist 8-hydroxy-2-(N,N-di-n-propylamino)tetralin. Xenobiotica 1995, 25, 1371-1380.
13. Al Neirabeyeh, M.; Reynaud, D.; Podona, T.; Ou, L.; Perdicakis, C.; Coudert, G.; Guillaumet, G.; Pichat, L.; Gharib, A.; Sarda, N. Methoxy and hydroxy derivatives of 3,4-dihydro-3-(di-n-propylamino)-2H-1-benzopyrans: new synthesis and dopaminergic activity. Eur. J. Med. Chem. 1991, 26, 497-504.
14. Hacksell, U.; Svensson, U.; Nilsson, J. L.; Hjorth, S.; Carlsson, A.; Wikström, H.; Linderberg, P.; Sanchez, D. N-Alkylated 2-aminotetralins: Central dopamine-receptor stimulating activity. J. Med. Chem. 1979, 22, 1469-1475.
15. 1A Receptors. J. Med. Chem. 1996, 39, 4036-4043.
16. 1A Receptors. J. Med. Chem. 1993, 36, 4221-4229.
17. TSAR V3.21; Oxford Molecular Ltd., The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, England.
18. (a) SIMCA 7.01; Umetri AB, Box 7960, S-907 19 Umeå, Sweden.
19. (b) The cross-validation was performed according to the SIMCA 7.0 defaults. In short, parts of the data were kept out of the model development and subsequently predicted by the model and then compared with the actual values. This procedure is repeated until every observation has been kept out once. A component is considered significant if Q2(1.0 - PRESS (prediction error sum of squares))/SS (residual sum of squares of previous dimension) is greater than a significant limit (0.097).
20. 1A = 8.718 + 0.000225VampSA + 0.005979VampMP - 0.22291VampIP - 0.33964LUMO + 0.22291HOMO - 0.09746Tdipol + 0.001249Vol + 0.045927logP + 0.001181Tlipol + 0.002782MR - 0.00475AreaS1 - 0.00691VolS1 - 0.00234EVolS1 - 0.03079BdipolS1 - 0.1117logPS1 - 0.04736BLipolS1 - 0.02018MRS1 - 0.17818HdonS1 + 0.11657HaccS1 + 0.005035AreaS2 + 0.008016VolS2 + 0.007185EVolS2 + 0.38861BDIPOLS2 + 0.32498logPS2 + 0.099656BLipolS2 + 0.023759MRS2 + 0.002031AreaS3 + 0.003062VolS3 + 0.00254EVoS3 + 0.30028BDipolS3 + 0.072402logPS3 + 0.034971BLipolS3 + 0.00923MRS3
21. 1A.
22. 1A Receptor Ligands and Potential Anxiolytic Agents. 1 Synthesis and Structure-Activity Relationship Studies. J. Med. Chem. 1994, 37, 1179.
23. Norrestam, R. STOEABS, Program for Absorption Correction of STOE Data; Stockholm University: Sweden; personal communication.
24. Sheldrick, G. M. Phase Annealing in SHELX-90: Direct Methods for Larger Structures. Acta Crystallogr. 1990, A46, 467-473.
25. Sheldrick, G. M. SHELX-76, Program for Crystal Structure Determination; University of Cambridge: England, 1976.
26. Hamilton, W. C. Significance test on the crystallographic R factor. Acta Crystallogr. 1965, 18, 502-510
27. Rogers, D. On the application of Hamilton's ratio test to the assignment of absolute configuration and an alternative test. Acta Crystallogr. 1981, A37, 734-741.
28. Bijvoet, J. M.; Peerdeman, A. F.; van Bommel, A. J. Determination of the Absolute Configuration of Optically Active Compounds by Means of X-rays. Nature (London) 1951, 168, 271-272.
29. Jackson, D. M.; Mohell, N.; Georgiev, J.; Bengtsson, A.; Larsson, L.-G.; Magnusson, O.; Ross, S. B. Time course of bromocriptine induced excitation in rat: behavioural and biochemical studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 35, 146-155.
30. 1A receptor antagonist. Eur. J. Pharmacol. 1998, 360, 219-225.
31. Munson, P. J.; Rodbard, D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-239.
32. 1A Receptor Antagonist, NAD-299. J. Pharmacol. Exp.Ther. 1997, 283, 216-225.
33. 3 Receptors. Mol. Pharmacol. 1993, 43, 749-754.
34. Albert, P. R.; Zhou, Q.-Y.; Van To, H. H. M.; Bunzow, J. R.; Civelli, O. Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine la receptor gene. J. Biol. Chem. 1990, 265, 5825-5832.
35. 1A receptors coupled to adenylyl cyclase are a model for the postsynaptic receptors in the rat hippocampus. Br. J. Pharmacol. 1992, 107, 141-145.
36. Dorflinger, L. J.; Schonbrunn, A. Somatostatin inhibits vasoactive intestinal peptide-stimulated cyclic adenosine monophosphate accumulation in GH pituitary cells. Endocrinology 1983, 113, 1541-1550.
37. Brown, B. L.; Ekins, P.; Albano, J. D. M. Saturation assays for cyclic AMP using endogenous binding protein. Adv. Cycl. Nucleotide Res. 1972, 2, 25-40.
38. Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal. Biochem. 1990, 89, 231-234.